Structural determinants for activity of the antidepressant vortioxetine at human and rodent 5-HT


Journal

Nature structural & molecular biology
ISSN: 1545-9985
Titre abrégé: Nat Struct Mol Biol
Pays: United States
ID NLM: 101186374

Informations de publication

Date de publication:
02 May 2024
Historique:
received: 13 12 2022
accepted: 19 03 2024
medline: 3 5 2024
pubmed: 3 5 2024
entrez: 2 5 2024
Statut: aheadofprint

Résumé

Vortioxetine (VTX) is a recently approved antidepressant that targets a variety of serotonin receptors. Here, we investigate the drug's molecular mechanism of operation at the serotonin 5-HT

Identifiants

pubmed: 38698207
doi: 10.1038/s41594-024-01282-x
pii: 10.1038/s41594-024-01282-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Bang-Andersen, B. et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J. Med. Chem. 54, 3206–3221 (2011).
doi: 10.1021/jm101459g pubmed: 21486038
Sanchez, C., Asin, K. E. & Artigas, F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol. Ther. 145, 43–57 (2015).
doi: 10.1016/j.pharmthera.2014.07.001 pubmed: 25016186
Nackenoff, A. G. et al. Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed using the SERT Met172 mouse. ACS Chem. Neurosci. 8, 1092–1100 (2017).
doi: 10.1021/acschemneuro.7b00038 pubmed: 28272863
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y. & Keefe, R. S. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology 41, 2961 (2016).
doi: 10.1038/npp.2016.181 pubmed: 27725683 pmcid: 5061887
McIntyre, R. S., Lophaven, S. & Olsen, C. K. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 17, 1557–1567 (2014).
doi: 10.1017/S1461145714000546 pubmed: 24787143
Pehrson, A. L. et al. Treatment of cognitive dysfunction in major depressive disorder—a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. Eur. J. Pharmacol. 753, 19–31 (2015).
doi: 10.1016/j.ejphar.2014.07.044 pubmed: 25107284
Riga, M. S., Sánchez, C., Celada, P. & Artigas, F. Involvement of 5-HT 3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology 108, 73–81 (2016).
doi: 10.1016/j.neuropharm.2016.04.023 pubmed: 27106166
Nemecz, À., Prevost, M. S., Menny, A. & Corringer, P.-J. Emerging molecular mechanisms of signal transduction in pentameric ligand-gated ion channels. Neuron 90, 452–470 (2016).
doi: 10.1016/j.neuron.2016.03.032 pubmed: 27151638
Barnes, N. M. et al. International Union of Basic and Clinical Pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function. Pharmacol. Rev. 73, 310–520 (2021).
doi: 10.1124/pr.118.015552 pubmed: 33370241 pmcid: 7770494
Niesler, B. 5-HT3 receptors: potential of individual isoforms for personalised therapy. Curr. Opin. Pharmacol. 11, 81–86 (2011).
doi: 10.1016/j.coph.2011.01.011 pubmed: 21345729
Ladefoged, L. K. et al. Modeling and mutational analysis of the binding mode for the multimodal antidepressant drug vortioxetine to the human 5-HT3A receptor. Mol. Pharmacol. 94, 1421–1434 (2018).
doi: 10.1124/mol.118.113530 pubmed: 30257860
Polovinkin, L. et al. Conformational transitions of the serotonin 5-HT3 receptor. Nature 563, 275–279 (2018).
doi: 10.1038/s41586-018-0672-3 pubmed: 30401839 pmcid: 6614044
Basak, S. et al. Cryo-EM structure of 5-HT 3A receptor in its resting conformation. Nat. Commun. 9, 514 (2018).
doi: 10.1038/s41467-018-02997-4 pubmed: 29410406 pmcid: 5802770
Basak, S., Gicheru, Y., Rao, S., Sansom, M. S. P. & Chakrapani, S. Cryo-EM reveals two distinct serotonin-bound conformations of full-length 5-HT3A receptor. Nature 563, 270–274 (2018).
doi: 10.1038/s41586-018-0660-7 pubmed: 30401837 pmcid: 6237196
Felt, K. et al. Structural basis for partial agonism in 5-HT3A receptors. Nat. Struct. Mol. Biol. https://doi.org/10.1038/s41594-023-01140-2 (2024).
doi: 10.1038/s41594-023-01140-2 pubmed: 38580848
Zhang, Y. et al. Asymmetric opening of the homopentameric 5-HT 3A serotonin receptor in lipid bilayers. Nat. Commun. 12, 1–15 (2021).
Zarkadas, E. et al. The binding of palonosetron and other antiemetic drugs to the serotonin 5-HT3 receptor. Structure 28, 1131–1140 (2020).
doi: 10.1016/j.str.2020.07.004 pubmed: 32726573
Basak, S. et al. High-resolution structures of multiple 5-HT3AR-setron complexes reveal a novel mechanism of competitive inhibition. eLife 9, e57870 (2020).
doi: 10.7554/eLife.57870 pubmed: 33063666 pmcid: 7655109
Dale, E. et al. The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: an in vitro study in rat hippocampus slices. Brain Res. 1689, 1–11 (2018).
doi: 10.1016/j.brainres.2017.12.025 pubmed: 29274875
Gielen, M. & Corringer, P.-J. The dual-gate model for pentameric ligand-gated ion channels activation and desensitization. J. Physiol. 596, 1873–1902 (2018).
doi: 10.1113/JP275100 pubmed: 29484660 pmcid: 5978336
Beene, D. L. et al. Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry 41, 10262–10269 (2002).
doi: 10.1021/bi020266d pubmed: 12162741
Xiu, X., Puskar, N. L., Shanata, J. A. P., Lester, H. A. & Dougherty, D. A. Nicotine binding to brain receptors requires a strong cation-pi interaction. Nature 458, 534–537 (2009).
doi: 10.1038/nature07768 pubmed: 19252481 pmcid: 2755585
Thompson, A. J. Recent developments in 5-HT3 receptor pharmacology. Structure 34, 100–109 (2013).
Laverty, D. et al. Cryo-EM structure of the human α1β3γ2 GABAA receptor in a lipid bilayer. Nature 565, 516–520 (2019).
doi: 10.1038/s41586-018-0833-4 pubmed: 30602789
Kim, J. J. et al. Shared structural mechanisms of general anaesthetics and benzodiazepines. Nature 585, 303–308 (2020).
doi: 10.1038/s41586-020-2654-5 pubmed: 32879488 pmcid: 7486282
Talwar, S. & Lynch, J. W. Investigating ion channel conformational changes using voltage clamp fluorometry. Neuropharmacology 98, 3–12 (2015).
doi: 10.1016/j.neuropharm.2015.03.018 pubmed: 25839896
Cowgill, J. & Chanda, B. The contribution of voltage clamp fluorometry to the understanding of channel and transporter mechanisms. J. Gen. Physiol. 151, 1163–1172 (2019).
doi: 10.1085/jgp.201912372 pubmed: 31431491 pmcid: 6785729
Munro, L. et al. Conformational changes in the 5-HT3A receptor extracellular domain measured by voltage-clamp fluorometry. Mol. Pharmacol. 96, 720–734 (2019).
doi: 10.1124/mol.119.116657 pubmed: 31582575
Chang, Y. & Weiss, D. S. Site-specific fluorescence reveals distinct structural changes with GABA receptor activation and antagonism. Nat. Neurosci. 5, 1163–1168 (2002).
doi: 10.1038/nn926 pubmed: 12368804
Lefebvre, S. N., Taly, A., Menny, A., Medjebeur, K. & Corringer, P.-J. Mutational analysis to explore long-range allosteric couplings involved in a pentameric channel receptor pre-activation and activation. eLife 10, e60682 (2021).
doi: 10.7554/eLife.60682 pubmed: 34590583 pmcid: 8504973
Muroi, Y., Czajkowski, C. & Jackson, M. B. Local and global ligand-induced changes in the structure of the GABA(A) receptor. Biochemistry 45, 7013–7022 (2006).
doi: 10.1021/bi060222v pubmed: 16752892
Pless, S. A. & Lynch, J. W. Ligand-specific conformational changes in the alpha1 glycine receptor ligand-binding domain. J. Biol. Chem. 284, 15847–15856 (2009).
doi: 10.1074/jbc.M809343200 pubmed: 19286654 pmcid: 2708881
Fakhfouri, G., Rahimian, R., Dyhrfjeld-Johnsen, J., Zirak, M. R. & Beaulieu, J.-M. 5-HT3 Receptor antagonists in neurologic and neuropsychiatric disorders: the iceberg still lies beneath the surface. Pharmacol. Rev. 71, 383–412 (2019).
doi: 10.1124/pr.118.015487 pubmed: 31243157
Hassaine, G. et al. Large scale expression and purification of the mouse 5-HT3 receptor. Biochim. Biophys. Acta 1828, 2544–2552 (2013).
doi: 10.1016/j.bbamem.2013.05.028 pubmed: 23747684
Hassaïne, G. et al. Expression, biochemistry, and stabilization with camel antibodies of membrane proteins: case study of the mouse 5-HT3 receptor. Methods Mol. Biol. 1635, 139–168 (2017).
doi: 10.1007/978-1-4939-7151-0_8 pubmed: 28755368
Grychowska, K. et al. Superiority of the triple-acting 5-HT6R/5-HT3R antagonist and MAO-B reversible inhibitor PZ-1922 over 5-HT6R antagonist intepirdine in alleviation of cognitive deficits in rats. J. Med. Chem. 66, 14928–14947 (2023).
doi: 10.1021/acs.jmedchem.3c01482 pubmed: 37797083
Uchański, T. et al. Megabodies expand the nanobody toolkit for protein structure determination by single-particle cryo-EM. Nat. Methods 18, 60–68 (2021).
doi: 10.1038/s41592-020-01001-6 pubmed: 33408403 pmcid: 7611088
Kandiah, E. et al. CM01: a facility for cryo-electron microscopy at the European Synchrotron. Acta Crystallogr D. Struct. Biol. 75, 528–535 (2019).
doi: 10.1107/S2059798319006880 pubmed: 31205015 pmcid: 6580229
Wagner, T. et al. SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-EM. Commun. Biol. https://doi.org/10.1038/s42003-019-0437-z (2019).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
doi: 10.1038/nmeth.4169 pubmed: 28165473
Croll, T. I. & Read, R. J. Adaptive Cartesian and torsional restraints for interactive model rebuilding. Acta Crystallogr. D 77, 438–446 (2021).
doi: 10.1107/S2059798321001145
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Biol. Crystallogr. 66, 486–501 (2010).
doi: 10.1107/S0907444910007493
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D 75, 861–877 (2019).
doi: 10.1107/S2059798319011471
Wu, E. L. et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 1997–2004 (2014).
doi: 10.1002/jcc.23702 pubmed: 25130509 pmcid: 4165794
Best, R. B. et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone ϕ, ψ and side-chain χ1 and χ2 dihedral angles. J. Chem. Theory Comput. 8, 3257–3273 (2012).
doi: 10.1021/ct300400x pubmed: 23341755 pmcid: 3549273
Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 79, 926–935 (1983).
doi: 10.1063/1.445869
Phillips, J. C. et al. Scalable molecular dynamics on CPU and GPU architectures with NAMD. J. Chem. Phys. 153, 044130 (2020).
doi: 10.1063/5.0014475 pubmed: 32752662 pmcid: 7395834
Feller, S. E., Zhang, Y., Pastor, R. W. & Brooks, B. R. Constant pressure molecular dynamics simulation: the Langevin piston method. J. Chem. Phys. 103, 4613–4621 (1995).
doi: 10.1063/1.470648
Darden, T., York, D. & Pedersen, L. Particle mesh Ewald: an N⋅log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089–10092 (1993).
doi: 10.1063/1.464397
Miyamoto, S. & Kollman, P. A. Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comput. Chem. 13, 952–962 (1992).
doi: 10.1002/jcc.540130805
Andersen, H. C. Rattle: A ‘velocity’ version of the shake algorithm for molecular dynamics calculations. J. Comput. Phys. 52, 24–34 (1983).
doi: 10.1016/0021-9991(83)90014-1
Balusek, C. et al. Accelerating membrane simulations with hydrogen mass repartitioning. J. Chem. Theory Comput. 15, 4673–4686 (2019).
doi: 10.1021/acs.jctc.9b00160 pubmed: 31265271 pmcid: 7271963
Tuckerman, M., Berne, B. J. & Martyna, G. J. Reversible multiple time scale molecular dynamics. J. Chem. Phys. 97, 1990–2001 (1992).
doi: 10.1063/1.463137
Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33–38, 27–8 (1996).
Smart, O. S., Neduvelil, J. G., Wang, X., Wallace, B. A. & Sansom, M. S. HOLE: a program for the analysis of the pore dimensions of ion channel structural models. J. Mol. Graph. 14, 354–360, 376 (1996).
doi: 10.1016/S0263-7855(97)00009-X pubmed: 9195488
Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108 (1973).
doi: 10.1016/0006-2952(73)90196-2 pubmed: 4202581

Auteurs

Uriel López-Sánchez (U)

University Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France.
Program in Cellular and Molecular Medicine, Boston Children's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.

Lachlan Jake Munro (LJ)

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Lucy Kate Ladefoged (LK)

Department of Chemistry, Aarhus University, Aarhus, Denmark.

Anders Juel Pedersen (AJ)

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Christian Colding Brun (CC)

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Signe Meisner Lyngby (SM)

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Delphine Baud (D)

University Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France.

Céline Juillan-Binard (C)

University Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France.

Miriam Grønborg Pedersen (MG)

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.

Sarah C R Lummis (SCR)

Department of Biochemistry, University of Cambridge, Cambridge, UK.

Benny Bang-Andersen (B)

Lundbeck Research, H. Lundbeck A/S, Valby, Denmark.

Birgit Schiøtt (B)

Department of Chemistry, Aarhus University, Aarhus, Denmark.

Christophe Chipot (C)

Université de Lorraine, CNRS, LPCT, Nancy, France.
Laboratoire International Associé CNRS and University of Illinois at Urbana-Champaign, Vandoeuvre-les-Nancy, France.
Department of Physics, University of Illinois at Urbana-Champaign, Urbana, IL, USA.

Guy Schoehn (G)

University Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France.

Jacques Neyton (J)

University Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France.

Francois Dehez (F)

Université de Lorraine, CNRS, LPCT, Nancy, France.
Laboratoire International Associé CNRS and University of Illinois at Urbana-Champaign, Vandoeuvre-les-Nancy, France.

Hugues Nury (H)

University Grenoble Alpes, CNRS, CEA, IBS, Grenoble, France. hugues.nury@ibs.fr.

Anders S Kristensen (AS)

Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark. ask@sund.ku.dk.

Classifications MeSH